Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Acta Biochim Pol ; 68(3): 359-375, 2021 Aug 31.
Artigo em Inglês | MEDLINE | ID: mdl-34464044

RESUMO

Seminal demonstration of the possibility of stable genetic modification of mammalian cells performed by Waclaw and Elisabeth Szybalski opened the doors for gene therapy, the term coined by Waclaw Szybalski already in 1962. In the next 60 years, numerous tools for gene delivery have been developed and applied for clinical research, culminating in the registration of several genetic therapies in Europe and the USA. Some of these strategies, aimed to treat severe combined immunodeficiencies, inherited forms of blindness, spinal muscular atrophy, some cancers, and genetic anemias, are the real hope for patients suffering from previously incurable diseases or the ones whose treatment was not effective. On the approaching 60th anniversary of gene therapy, combined with the 100th anniversary of the birth of Professor Waclaw Szybalski (September 9th, 1921), who passed away on December 16, 2020, here I present the summary of the most important aspects of clinical applications of genetic therapies.


Assuntos
Terapia Genética/história , Animais , Europa (Continente) , Terapia Genética/métodos , História do Século XX , História do Século XXI , Humanos , Camundongos , Atrofia Muscular Espinal/história , Atrofia Muscular Espinal/terapia , Imunodeficiência Combinada Severa/história , Imunodeficiência Combinada Severa/terapia , Estados Unidos , Talassemia beta/história , Talassemia beta/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA